Clinical trial
A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway
NCT05578092
Study timeline
Study start (actual)2022-12-02Date precision: day
Registry last updated2026-02-19
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Solid Tumorunresolved
Advanced Solid Tumorunresolved
Non Small Cell Lung Cancerunresolved
Colo-rectal Cancerunresolved
Interventions
Sponsors & collaborators
Mirati Therapeutics Inc.lead sponsor
Mapped research locations
NashvilleTennessee, United States2HoustonTexas, United States1DallasTexas, United States1BaltimoreMaryland, United States1SeattleWashington, United States1PittsburghPennsylvania, United States1CincinnatiOhio, United States1PortlandOregon, United States1OrlandoFlorida, United States1New HavenConnecticut, United States1RochesterMinnesota, United States1Fort WorthTexas, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05578092 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.